Anti-angiogenic strategies in gastrointestinal malignancies

Current Treatment Options in Oncology

Volumn 6, Issue 5, 2005, Pages 411-421

  Whisenant, Jonathan ^a   Bergsland, Emily ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BASIC FIBROBLAST GROWTH FACTOR; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CELECOXIB; CETUXIMAB; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; GEFITINIB; GELATINASE A; GEMCITABINE; IRINOTECAN; OXALIPLATIN; PACLITAXEL; PLATELET DERIVED GROWTH FACTOR; RECOMBINANT ENDOSTATIN; SORAFENIB; SUNITINIB; THALIDOMIDE; TRASTUZUMAB; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN INHIBITOR; VATALANIB;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; BARRETT ESOPHAGUS; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL FEATURE; CLINICAL TRIAL; COLORECTAL CANCER; CORRELATION ANALYSIS; DIGESTIVE SYSTEM CANCER; DIGESTIVE SYSTEM PERFORATION; DRUG EFFICACY; DRUG INFUSION; DRUG SAFETY; DRUG TARGETING; DRUG TOLERANCE; ESOPHAGUS CANCER; GASTROINTESTINAL STROMAL TUMOR; HEPATOBILIARY SYSTEM CANCER; HUMAN; LIVER CELL CARCINOMA; LIVER METASTASIS; LYMPH NODE METASTASIS; METASTASIS POTENTIAL; NEUROENDOCRINE TUMOR; PANCREAS CANCER; PANCREAS ISLET CELL TUMOR; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; STOMACH CANCER; SURVIVAL TIME; TREATMENT OUTCOME; TUMOR GROWTH; TUMOR VOLUME; VENOUS THROMBOEMBOLISM;

EID: 28044473001     PISSN: 15272729     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11864-005-0044-8     Document Type: Review

References (96)

1. Auvinen MI, Sihvo EI, Ruohtula T, et al.: Incipient angiogenesis in Barrett's epithelium and lymphangiogenesis in Barrett's adenocarcinoma. J Clin Oncol 2002, 20:2971-2979.
2. Andre T, Kotelevets L, Vaillant JC, et al.: Vegf, Vegf-B, Vegf-C and their receptors KDR, FLT-1 and FLT-4 during the neoplastic progression of human colonic mucosa. Int J Cancer 2000, 86:174-181.
3. Takahashi Y, Tanaka LM, Kitadai M: Expression of vascular endothelial growth factor and angiogenesis in gastrointestinal stromal tumor of the stomach. Oncology 2003, 64:266-274.
4. Scappaticci FA: Mechanisms and future directions for angiogenesis-based cancer therapies. J Clin Oncol 2002, 20:3906-3927.
5. Folkman J: Tumor angiogenesis: a possible control point in tumor growth. Ann Intern Med 1975, 82:96-100.
6. Hanahan D, Folkman J: Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996, 86:353-364.
7. Lyden D, Hattori K, Dias S, et al.: Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat Med 2001, 7:1194-201.
8. Stoll BR, Migliorini C, Kadambi A, et al.: A mathematical model of the contribution of endothelial progenitor cells to angiogenesis in tumors: implications for antiangiogenic therapy. Blood 2003, 102:2555-61.
9. Carmeliet P: Angiogenesis in health and disease. Nat Med 2003, 9:653-660.
10. Ferrara N: Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications. Semin Oncol 2002, 29(6 Suppl 16):10-14.
11. Hurwitz H, Fehrenbacher L, Novotny W, et al.: BV plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004, 350:2335-2342.
12. Ogata Y, Fujita H, Yamana H, et al.: Expression of vascular endothelial growth factor as a prognostic factor in nodepositive squamous cell carcinoma in the thoracic esophagus: long-term follow-up study. World J Surg 2003, 27:584-589.
13. Spence GM, Graham AN, Mulholland K, et al.: Bone marrow micrometastases and markers of angiogenesis in esophageal cancer [discussion 50]. Ann Thorac Surg 2004, 78:1944-1949.
14. Couvelard A, Paraf F, Gratio V, et al.: Angiogenesis in the neoplastic sequence of Barrett's oesophagus. Correlation with VEGF expression. J Pathol 2000, 192:14-18.
15. Du JR, Jiang Y, Zhang YM, et al.: Vascular endothelial growth factor and microvascular density in esophageal and gastric carcinomas. World J Gastroenterol 2003, 9:1604-1606.
16. Lord RV, Park IM, Wickramasinghe K, et al.: Vascular endothelial growth factor and basic fibroblast growth factor expression in esophageal adenocarcinoma and Barrett esophagus. J Thorac Cardiovasc Surg 2003 125:246-253.
17. Spence GM, Graham AN, Mulholland K, et al.: Bone marrow micrometastases and markers of angiogenesis in esophageal cancer [discussion 1950]. Ann Thorac Surg 2004, 78:1944-1949.
18. Wang L, Yu J, Ni J, et al.: Extracellular matrix protein 1 (ECM1) is over-expressed in malignant epithelial tumors. Cancer Lett 2003, 200:57-67.
19. Nagata J, Kijima H, Hatanaka H, et al.: Angiopoietin-1 and vascular endothelial growth factor expression in human esophageal cancer. Int J Mol Med 2002, 10:423-426.
20. Yoshikawa T, Tsuburaya A, Kobayashi O, et al.: Plasma concentrations of VEGF and bFGF in patients with gastric carcinoma. Cancer Lett 2000, 153:7-12.
21. Maeda K, Chung YS, Ogawa Y, et al.: Prognostic value of vascular endothelial growth factor expression in gastric carcinoma. Cancer 1996, 77:858-863.
22. Maehara Y, Kabashima A, Koga T, et al.: Vascular invasion and potential for tumor angiogenesis and metastasis in gastric carcinoma. Surgery 2000, 128:408-416.
23. Koga T, Shibahara K, Kabashima A, et al.: Overexpression of cyclooxygenase-2 and tumor angiogenesis in human gastric cancer. Hepatogastroenterology 2004, 51:1626-1630.
24. Araya M, Terashima M, Takagane A, et al.: Microvessel count predicts metastasis and prognosis in patients with gastric cancer. J Surg Oncol 1997, 65:232-236.
25. Takahashi Y, Cleary KR, Mai M, et al.: Significance of vessel count and vascular endothelial growth factor and its receptor (KDR) in intestinal-type gastric cancer. Clin Cancer Res 1996, 2:1679-1684.
26. Takahashi Y, Bucana CD, Akagi Y, et al.: Significance of platelet-derived endothelial cell growth factor in the angiogenesis of human gastric cancer. Clin Cancer Res 1998, 4:429-434.
27. Furuse J, Maru Y, Yoshino M, et al.: Assessment of arterial tumor vascularity in small hepatocellular carcinoma. Comparison between color doppler ultrasonography and radiographic imagings with contrast medium: dynamic CT, angiography, and CT hepatic arteriography. Eur J Radiol 2000, 36:20-27.
28. Mikami S, Kubo S, Hirohashi K, et al.: Computed tomography during arteriography and arterial portography in small hepatocellular carcinoma and dysplastic nodule: a prospective study. Jpn J Cancer Res 2000, 91:859-863.
29. Mise M, Arii S, Higashituji H, et al.: Clinical significance of vascular endothelial growth factor and basic fibroblast growth factor gene expression in liver tumor. Hepatology 1996, 23:455-464.
30. Kanematsu M, Semelka RC, Leonardou P, et al.: Angiogenesis in hepatocellular nodules: correlation of MR imaging and vascular endothelial growth factor. J Magn Reson Imaging 2004, 20:426-434.
31. Yamaguchi R, Yano H, Iemura A, et al.: Expression of vascular endothelial growth factor in human hepatocellular carcinoma. Hepatology 1998, 28:68-77.
32. Poon RT, Ho JW, Tong CS, et al.: Prognostic significance of serum vascular endothelial growth factor and endostatin in patients with hepatocellular carcinoma. Br J Surg 2004, 91:1354-1360.
33. Cui J, Dong BW, Liang F, et al.: Effect of c-myc, Ki-67, MMP-2 and VEGF expression on prognosis of hepatocellular carcinoma patients undergoing tumor resection. World J Gastroenterol 2004, 10:1533-1536.
34. Zhou XD: Recurrence and metastasis of hepatocellular carcinoma: progress and prospects. Hepatobiliary Pancreat Dis Int 2002, 1:35-41.
35. An FQ, Matsuda M, Fujii H, Matsumoto Y: Expression of vascular endothelial growth factor in surgical specimens of hepatocellular carcinoma. J Cancer Res Clin Oncol 2000, 126:153-160.
36. Kawahara N, Ono M, Taguchi K, et al.: Enhanced expression of thrombospondin-1 and hypovascularity in human cholangiocarcinoma. Hepatology 1998, 28:1512-1517.
37. Okita S, Kondoh S, Shiraishi K, et al.: Expression of vascular endothelial growth factor correlates with tumor progression in gallbladder cancer. Int J Oncol 1998, 12:1013-1018.
38. Quan ZW, Wu K, Wang J, et al.: Association of p53, p 16, and vascular endothelial growth factor protein expressions with the prognosis and metastasis of gallbladder cancer. J Am Coll Surg 2001, 193:380-383.
39. Yue SQ, Yang YL, Zhou JS, et al.: Relationship between urokinase-type plasminogen activator receptor and vascular endothelial growth factor expression and metastasis of gallbladder cancer. World J Gastroenterol 2004, 10:2750-2752.
40. Fujimoto K, Hosotani R, Wada M, et al.: Expression of two angiogenic factors, vascular endothelial growth factor and platelet-derived endothelial cell growth factor in human pancreatic cancer, and its relationship to angiogenesis. Eur J Cancer 1998, 34:1439-1447.
41. Niedergethmann M, Hildenbrand R, Wostbrock B, et al.: High expression of vascular endothelial growth factor predicts early recurrence and poor prognosis after curative resection for ductal adenocarcinoma of the pancreas. Pancreas 2002, 25:122-129.
42. Reinmuth N, Parikh AA, Ahmad SA, et al.: Biology of angiogenesis in tumors of the gastrointestinal tract. Microsc Res Tech 2003, 60:199-207.
43. Marion-Audibert AM, Barel C, Gouysse G, et al.: Low microvessel density is an unfavorable histoprognostic factor in pancreatic endocrine tumors. Gastroenterology 2003, 125:1094-1104.
44. Lim YJ, Lee JK, Park CK, et al.: Prognostic value of VEGF in human pancreatic ductal adenocarcinoma. Korean J Intern Med 2004, 19:10-14.
45. Li M, Yang H, Chai H, et al.: Pancreatic carcinoma cells express neuropillins and vascular endothelial growth factor, but not vascular endothelial growth factor receptors. Cancer 2004, 101:2341-2350.
46. Fukahi K, Fukasawa M, Neufeld G, et al.: Aberrant expression of neuropilin-1 and -2 in human pancreatic cancer cells. Clin Cancer Res 2004, 10:581-590.
47. Schuch G, Kisker O, Atala A, et al.: Pancreatic tumor growth is regulated by the balance between positive and negative modulators of angiogenesis. Angiogenesis 2002, 5:181-190.
48. Baker CH, Solorzano CC, Fidler IJ: Blockade of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling for therapy of metastatic human pancreatic cancer. Cancer Res 2002, 62:1996-2003.
49. Buchler P, Reber HA, Ullrich A, et al.: Pancreatic cancer growth is inhibited by blockade of VEGF-RII. Surgery 2003, 134:772-782.
50. Tsuzuki Y, Mouta Carreira C, Bockhorn M, et al.: Pancreas microenvironment promotes VEGF expression and tumor growth: novel window models for pancreatic tumor angiogenesis and microcirculation. Lab Invest 2001, 81:1439-1451.
51. Kuwahara K, Sasaki T, Kuwada Y, et al.: Expression of angiogenic factors in pancreatic ductal carcinoma: a correlative study with clinicopathologic parameters and patient survival. Pancreas 2003, 26:344-349.
52. Kuniyasu H, Abbruzzese JL, Cleary KR, et al.: Induction of ductal and stromal hyperplasia by basic fibroblast growth factor produced by human pancreatic carcinoma. Int J Oncol 2001, 19:681-685.
53. Ohta T, Yamamoto M, Numata M, et al.: Expression of basic fibroblast growth factor and its receptor in human pancreatic carcinomas. Br J Cancer 1995, 72:824-831.
54. Takahashi R, Tanaka S, Kitadai Y, et al.: Expression of vascular endothelial growth factor and angiogenesis in gastrointestinal stromal tumor of the stomach. Oncology 2003, 64:266-274.
55. Jubb A, Landon T, Burwick J, et al.: Quantitative analysis of colorectal tissue microarrays by immunofluorescence and in situ hybridization. J Pathol 2003, 200:577-588.
56. Fox S, Whalen G, Sanders M, et al.: Angiogenesis in normal tissue adjacent to colon cancer. J Surg Oncol 1998, 69:230-234.
57. Brown LF, Berse B, Jackman RW, et al.: Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in adenocarcinomas of the gastrointestinal tract. Cancer Res 1993, 53:4727-4735.
58. Cassano A, Bagala C, Battelli C, et al.: Expression of vascular endothelial growth factor, mitogen-activated protein kinase and p53 in human colorectal cancer. Anticancer Res 2002, 22:2179-2184.
59. Lee JC, Chow NH, Wang ST, et al.: Prognostic value of vascular endothelial growth factor expression in colorectal cancer patients. Eur J Cancer 2003, 36:748-753.
60. Cascinu S, Staccioli MP, Gasparini G, et al.: Expression of vascular endothelial growth factor can predict event-free survival in stage II colon cancer. Clin Cancer Res 2000, 6:2803-2807.
61. Cascinu S, Graziano F, Valentini M, et al.: Differences of vascular endothelial growth factor (VEGF) expression between liver and abdominal metastases from colon cancer. Implications for the treatment with VEGF inhibitors. Clin Exp Metastasis 2000, 18:651-655.
62. Takahashi Y, Tucker SL, Kitadai Y, et al.: Vessel counts and expression of vascular endothelial growth factor as prognostic factors in node-negative colon cancer. Arch Surg 1997, 132:541-546.
63. Cassano A, Bagala C, Battelli C, et al.: Expression of vascular endothelial growth factor, mitogen-activated protein kinase and p53 in human colorectal cancer. Anticancer Res 2002, 22:2179-2184.
64. Duff SE, Jeziorska M, Haboubi N, Kumar S, et al.: Evidence for redundancy, cross-talk and autocrine circuits within the vascular endothelial growth factor signaling pathways in colorectal cancer [abstract 255]. Proc ASCO 2004, 22:14s.
65. Ton N, Jayson GC: Resistance to anti-VEGF agents. Curr Pharm Des 2004, 10:51-64.
66. Tsuji T, Sawai T, Yamashita H, et al.: Platelet-derived endothelial cell growth factor expression is an independent prognostic factor in colorectal cancer patients after curative surgery. Eur J Surg Oncol 2004, 30:296-302.
67. Reinmuth N, Fan F, Liu W, et al.: Impact of insulin-like growth factor receptor-I function on angiogenesis, growth, and metastasis of colon cancer. Lab Invest 2002, 82:1377-1389.
68. Wu Y, Yakar S, Zhao L, et al.: Circulating insulin-like growth factor-I levels regulate colon cancer growth and metastasis. Cancer Res, 2002, 62:1030-1035.
69. Sinicrope R, Gill S: Role of cyclooxygenase-2 in colorectal cancer. Cancer Metastasis Rev 2004, 23:63-75.
70. Subbaramaiah K, Dannenberg A: Cyclooxygenase 2: a molecular target for cancer prevention and treatment. Trends Pharmacol Sci 2003, 24:96-102.
71. Etoh T, Shibuta K, Barnard G, et al.: Angiogenin expression in human colorectal cancer: the role of focal macrophage infiltration. Clin Cancer Res 2000, 6:3545-3551.
72. Iqbal S, Lenz HJ: Angiogenesis inhibitors in the treatment of colorectal cancer. Semin Oncol 2004, 31:10-16.
73. St. Croix B, Rago C, Velculescu V, et al.: Genes expressed in human tumor endothelium. Science 2000, 289:1197-1202.
74. Terris B, Scoazec JY, Rubbia L, et al.: Expression of vascular endothelial growth factor in digestive neuroendocrine tumours. Histopathology 1998, 32:133-138.
75. Shah MA, Ilson D, Saltz L, et al.: A multicenter phase II study of irinotecan, cisplatin, and BV in patients with unresectable or metastatic gastric or gastroesophageal adenocarcinoma [abstract 26]. Proc Am Soc Clin Oncol-Gastrointestinal Cancers Symposium 2005, 23:314s.
76. Lin A, Brophy N, Fisher G, et al.: Phase II study of thalidomide in patients with unresectable hepatocellular carcinoma. Cancer 2005, 103:119-125.
77. Patt YZ, Hassan MM, Lozano RD, et al.: Thalidomide in the treatment of patients with hepatocellular carcinoma: a phase II trial. Cancer 2005, 103:749-755.
78. Schwartz J, Schwartz M, Goldman J, et al.: BV in hepatocellular carcinoma (HCC) for patients without metastasis and without invasion of the portal vein [abstract 134]. Proc ASCO Gastrointestinal Cancers Symposium 2005, 23:338s.
79. Britten c, Finn R, Gomes A, et al.: A pilot study of IV BV in hepatocellular cancer patients undergoing chemoembolisation [abstract 4138]. Proc ASCO 2005, 23:342s.
80. Wang L, Abou-Alfa G, Liu F, et al.: Novel methodology of response assessment in hepatocellular carcinoma-Assessing response by change in tumor enhancement in distinction from conventional means [abstract 3107]. Proc ASCO 2004, 22:14s.
81. Kindler HL, Friberg G, Stadler WM, et al.: Bevacizumab (B) plus gemcitabine (G) in patient (pts) with advanced pancreatic cancer (PC): Updated results of a multicenter phase II trial [abstract 4009]. Proc ASCO 2004, 22:14S.
82. Crane CH, Ellis LM, Abbruzzese J, et al.: Phase I trial of BV with concurrent radiotherapy and capecitabine in locally advanced pancreatic adenocarcinomas [abstract 4033]. Proc Journal Clin Oncol 2005, 23:316s.
83. Kabbinavar FF, Schulz J, McCleod M, et al.: Addition of BV to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol 2005, 23:3697-3705.
84. Fernando N, Yu DJ, Morse M, et al.: A phase II study of oxaliplatin, capecitabine and BV in the treatment of metastatic colorectal cancer [abstract 3556]. Proc Am Soc Clin Oncol 2005, 23:260s.
85. Hochster H, Welles L, Hart L, et al.: Safety and efficacy of BV when added to oxaliplatin/fluoropyrimidine regimens as first-line treatment of metastatic colorectal cancer: TREE 1&2 studies [abstract 3515]. Proc ASCO 2005, 23:248s.
86. Giantonio BJ, Catalano PJ, Meropol NJ, et al.: High-dose BV in combination with FOLFOX4 improves survival in patients with previously treated advanced colorectal cancer: Results from the Eastern Cooperative Oncology Group (ECOG) study E3200 [abstract 169a]. Proc ASCO Gastrointestinal Cancers Symposium 2005, 23:1s.
87. Saltz L, Lenz HJ, Hochster H, et al.: Randomized phase II trial of cetuximab/BV/irinotecan versus cetuximab/BV in irinotecan-refractory colorectal caner [abstract 3508]. Proc ASCO 2005, 23:248s.
88. Chen HX, M. Boron L, Grochow, J, et al.: TRC Participating Investigators: BV (BV) plus 5-FU/leucovorin (FU/LV) for advanced colorectal cancer (CRC) that progressed after standard chemotherapies: An NCI Treatment Referral Center trial (TRC-0301) [abstract 3515]. Proc ASCO 2004, 22:14s.
89. Willett CG, Boucher Y, di Tomaso E, et al.: Direct evidence that the VEGF-specific antibody BV has antivascular effects in human rectal cancer. Nat Med, 2004, 10:145-147.
90. Steward WF, Thomas AL, Morgan B, et al.: Extended phase I study of the oral vascular endothelial growth factor (VEGF) receptor inhibitor PTK787/ZK 222584 in combination with oxaliplatin/5-fluorouracil (5-FU)/leucovorin as first line treatment for metastatic colorectal cancer [abstract 1098]. Proc ASCO 2003, 22:274.
91. Hecht J, Trarbach t, Jaeger E, et al.: A randomized double-blind, placebo-controlled, phase III study in patients with metastatic adenocarcinoma of the colon or rectum receiving first-line chemotherapy with oxaliplatin/5-fluorouracil/leucovorin and PTK787/ZK 222584 or placebo (CONFIRM-1) [abstract LBA3]. Proc ASCO 2005, 23:2s.
92. Demetri GD, van Oosterom AT, Blackstein M, et al.: Phase 3, multicenter, randomized, double-blind, placebo-controlled trial of SU11248 in patients (pts) following failure of imatinib for metastatic GIST [abstract 4000]. Proc ASCO 2005, 23:308s.
93. Mendel DB, Laird AD, Xin X, et al.: In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003, 9:327-337.
94. Kulke M, Bergsland E, Ryan DP, et al.: A phase II, open-label, safety pharmacokenetic, and efficacy study of recombinant human endostatin in patients with advanced neuroendocrine tumors. Proc ASCO 2003, 21:239.
95. Kulke M, Lenz HJ, Meropol NJ, et al.: A phase 2 study to evaluate the efficacy and safety of SU11248 in patients (pts) with unresectable neuroendocrine tumors (NETs) [abstract 4008]. Proc ASCO 2005, 23:310s.
96. Yao JC, Charnsangavej C, Faria SC, et al.: Rapid decrease in blood flow (BF), blood volume (BV), and vascular permeability (PS) in carcinoid patients treated with BV [abstract 3013]. Proc ASCO 2004, 22:14s.